AC
NTLA icon

Aristides Capital’s Intellia Therapeutics NTLA Stock Holding History

Aristides Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,600
Closed -$182K – 300
2024
Q4 		$182K Buy
+15,600
New +$243K 0.04% 258

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aristides Capital's NTLA Position: Q1 2025 in Review

Aristides Capital sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 15,600 shares — an estimated $182K sold.

Aristides Capital first reported a position in NTLA in Q4 2024 and held it in 1 quarter. The position peaked at $182K in Q4 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Aristides Capital reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aristides Capital sold 15,600 Intellia Therapeutics shares in Q1 2025, an estimated $182K.
  • Aristides Capital first reported a position in Intellia Therapeutics in Q4 2024 and held it in 1 quarter.
  • Aristides Capital's Intellia Therapeutics position peaked at $182K in Q4 2024.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.